3,4-diaminopyridine (3,4-DAP), known commercially as amifampridine, is a potassium channel inhibitor that is FDA-approved for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). This evidence concerns the gene KCNA3 and Lambert-Eaton myasthenic syndrome.